Law360, New York (March 20, 2009) -- The Federal Trade Commission has disclosed that it will not challenge a so-called reverse payment agreement between generic-drug makers Mylan Inc., Dr. Reddy’s Laboratories Inc. and Cobalt Pharmaceuticals Inc. on one side and Keppra maker UCB SA on the other.
In letters dated March 10 that were first reported on Friday by Dow Jones, the FTC's Bureau of Competition said that after reviewing the matter – which involves UCB's anti-epileptic...
